Core Insights - Seres Therapeutics has received up to $3.6 million in non-dilutive funding from CARB-X to support the development of an oral liquid formulation of SER-155, aimed at improving access for medically vulnerable patients, particularly those in intensive care who cannot take oral capsules [1][3][5] - SER-155 is being developed for patients undergoing allogeneic hematopoietic stem cell transplants (allo-HSCT) and has shown a 77% reduction in bacterial bloodstream infections (BSIs) compared to placebo in a Phase 1b study [2][5] - The development of a liquid formulation is expected to broaden the impact of SER-155 in additional high-risk patient populations susceptible to BSIs and antimicrobial resistant infections [3][5] Funding and Support - CARB-X, a global non-profit partnership, is providing funding to accelerate the development of antibacterial products, specifically targeting drug-resistant bacteria [1][4] - The funding is supported by various federal and international health organizations, including the U.S. Department of Health and Human Services and the UK Department of Health and Social Care [3][4] Clinical Development - SER-155 has received Breakthrough Therapy designation and Fast Track designation from the FDA, indicating its potential to significantly reduce the risk of infections in allo-HSCT patients [5][6] - The company is finalizing the clinical protocol for a well-powered, placebo-controlled Phase 2 study following positive feedback from the FDA [2][5] Company Background - Seres Therapeutics is focused on improving outcomes for medically vulnerable populations through live biotherapeutics and has previously developed VOWST™, the first FDA-approved orally administered microbiome therapeutic [5][6] - The company aims to evaluate SER-155 in various patient populations, including those undergoing autologous-HSCT, cancer patients with neutropenia, and patients in intensive care [6]

Core Insights - Lifecore Biomedical has signed an agreement to transfer commercial manufacturing of a leading injectable pharmaceutical product to its facilities, becoming the supplier of choice for this product after meeting regulatory requirements [1][2] - This marks the second agreement with the same multinational organization in recent months, indicating Lifecore's growing reputation for quality and reliability in sterile injectables [1][2] - Additionally, Lifecore has entered into a pre-clinical formulation development agreement with an early-stage biotech company, further expanding its early-stage program pipeline [2] Company Strategy - The commercial site transfer is part of Lifecore's growth strategy to expand its CDMO business and build long-term partnerships with leading global pharmaceutical companies [2] - The new agreement will broaden Lifecore's commercial customer base and increase capacity utilization while allowing entry into new modalities [2] - Lifecore aims to capitalize on strong industry momentum and strengthen its position as a trusted U.S.-based CDMO partner [3] Company Background - Lifecore Biomedical is a fully integrated CDMO specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [4] - The company has over 40 years of expertise and serves global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories [4]

Core Viewpoint - XORTX Therapeutics Inc. has successfully closed a registered direct offering, raising gross proceeds of US$1,102,500 for the sale of 1,750,000 common shares at a price of US$0.63 per share, which will be used for working capital and general corporate purposes [1][3]. Group 1: Offering Details - The offering included 572,470 common shares and 1,117,530 pre-funded warrants, with each warrant allowing the holder to acquire one common share at an exercise price of $0.001 [2]. - D. Boral Capital LLC acted as the sole placement agent for the offering and will receive 87,500 agent warrants, each exercisable into one common share at an exercise price of US$0.69 [4]. Group 2: Company Overview - XORTX is focused on developing innovative therapies for gout and progressive kidney disease, with three clinically advanced products: XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney injury associated with respiratory virus infections [7]. - The company is also developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy, targeting purine metabolism and xanthine oxidase to reduce uric acid production [7].

UASHAT, Canada, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Apuiat Wind Farm L.P., a 50-50 partnership between the Innu communities and Boralex Inc., is proud to announce that the Apuiat Wind Farm has reached commercial operation. The 200 MW facility is located on the Nitassinan (traditional territory) of the Uashat mak Mani-utenam First Nation. The wind project was initiated and co-developed by the Innu communities. It stands as their first national energy project and the first wind farm to be built in Québec’s Côte ...

REHOVOT, Israel and Hoboken, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate in the Stifel 2025 Healthcare Conference, to be held to be held at the Lotte New York Palace Hotel, New-York, NY on November 11–13, 2025. Mr. London is sched ...

TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”) is pleased to provide an update on the ongoing drilling program at the Company’s Mercur Gold Project (“Mercur”) in Utah and the Beartrack-Arnett Gold Project (“Beartrack-Arnett”) in Idaho. Highlights Mobilized a new core rig to Beartrack-Arnett bringing the total number of rigs drilling on the Company’s projects to four.At Mercur, received assay results from 16 additional drill holes with ...

The Product Expands Grayscale’s Market-Leading Position with the Broadest Suite of Digital Asset ETPs in the U.S.STAMFORD, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Grayscale Investments®, the world’s largest digital asset-focused investment platform*, today announced that Grayscale Solana Trust ETF (Ticker: GSOL) has begun trading on NYSE Arca as an ETP, making it the first of Grayscale's staking products to uplist under the new generic listing standards approved by the U.S. Securities and Exchange Commissi ...

Core Viewpoint - Tango Therapeutics, Inc. is set to report its third quarter 2025 financial results on November 4, 2025, at 9:00 am ET, prior to the opening of U.S. financial markets, and will not hold a conference call [1] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and advancing precision medicine for cancer treatment [2] - The company employs the genetic principle of synthetic lethality to identify and develop therapies targeting critical cancer-related objectives [2]

Core Viewpoint - ACM Research, Inc. anticipates preliminary unaudited revenue for Q3 2025 to be between $264 million and $267 million, reflecting a year-over-year growth of 29% to 31% [8] - Total shipments are expected to range from $257 million to $262 million, indicating a year-over-year change of flat to down 2% [8] Group 1: Financial Results - The actual unaudited results for Q3 2025 are pending completion of quarter-end closing procedures and review by an independent accounting firm [2] - ACM Shanghai, ACM's principal operating subsidiary, will release its unaudited financial results concurrently on the Shanghai Stock Exchange [1][2] Group 2: Company Structure - ACM holds a 74.6% equity interest in ACM Shanghai, which contributes a substantial majority of ACM's consolidated revenue and net income [3] - The financial results of ACM Shanghai are reported in RMB and may differ materially from ACM's consolidated results, which are prepared in U.S. dollars [3] Group 3: Business Overview - ACM develops, manufactures, and sells semiconductor process equipment, including cleaning, electroplating, and packaging tools, aimed at enhancing productivity and product yield for semiconductor manufacturers [5]

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation as a presenting company at BIO-Europe 2025. The event, Europe’s premier life sciences partnering conference, will take place November 3–5, 2025, at the Vienna Exhibition and Congress C ...